Fotivda

Chemical Nametivozanib
Dosage FormCapsule (oral; 1.34 mg, 0.89 mg)
Drug ClassKinase inhibitors
SystemUrinary
CompanyAVEO Pharmaceuticals, Inc.
Approval Year2021

Indication

  • Indicated for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.
Last updated on 3/15/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Fotivda (tivozanib) Prescribing Information2021AVEO Pharmaceuticals, Inc. Boston, MA